Potential value of tumor stiffness and sE-cadherin in predicting the response to neoadjuvant therapy in HER2-positive breast cancers

References

• Slamon DJ , Leyland-JonesB, ShakSet al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med.344(11), 783–792 (2001).
   PubMed Web of Science ®Google Scholar
• Diéras V , MilesD, VermaSet al. Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial. Lancet Oncol.18(6), 732–742 (2017).
   PubMed Web of Science ®Google Scholar
• Gianni L , PienkowskiT, ImYHet al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol.13(1), 25–32 (2012).
   PubMed Web of Science ®Google Scholar
• Sun X , WangXE, ZhangZPet al. Neoadjuvant therapy and sentinel lymph node biopsy in HER2-positive breast cancer patients: results from the PEONY trial. Breast Cancer Res. Treat.180(2), 423–428 (2020).
   PubMed Web of Science ®Google Scholar
• Cortazar P , ZhangL, UntchMet al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet384(9938), 164–172 (2014).
   PubMed Web of Science ®Google Scholar
• Spring LM , FellG, ArfeA. Pathologic complete response after neoadjuvant chemotherapy and impact on breast cancer recurrence and survival: a comprehensive meta-analysis. Clin. Cancer Res.26(12), 2838–2848 (2020).
   PubMed Web of Science ®Google Scholar
• Swaminathan V , MythreyeK, O’BrienETet al. Mechanical stiffness grades metastatic potential in patient tumor cells and in cancer cell lines. Cancer Res.71(15), 5075–5080 (2011).
   PubMed Web of Science ®Google Scholar
• Yoo J , SeoBK. Tumor stiffness measured by shear wave elastography correlates with tumor hypoxia as well as histologic biomarkers in breast cancer. Cancer Imaging20(1), 85 (2020).
   PubMed Web of Science ®Google Scholar
• Evans A , WhelehanP, ThomsonKet al. Differentiating benign from malignant solid breast masses: value of shear wave elastography according to lesion stiffness combined with greyscale ultrasound according to BI-RADS classification. Br. J. Cancer107(2), 224–229 (2012).
   PubMed Web of Science ®Google Scholar
• Jing H , ChengW, LiZYet al. Early evaluation of relative changes in tumor stiffness by shear wave elastography predicts the response to neoadjuvant chemotherapy in patients with breast cancer. J. Ultrasound Med.35(8), 1619–1627 (2016).
   PubMed Web of Science ®Google Scholar
• Cong R , LiJ, GuoS. A new qualitative pattern classification of shear wave elastograghy for solid breast mass evaluation. Eur. J. Radiol.87, 111–119 (2017).
   PubMed Web of Science ®Google Scholar
• Wang M , YangZ, LiuCet al. Differential diagnosis of breast category 3 and 4 nodules through BI-RADS classification in conjunction with shear wave elastography. Ultrasound Med. Biol.43(3), 601–606 (2017).
   PubMed Web of Science ®Google Scholar
• Wang W , ZhangJC, TianWSet al. Shear wave elastography-based ultrasomics: differentiating malignant from benign focal liver lesions. Abdom. Radiol. (NY)46(1), 237–248 (2021).
   PubMed Web of Science ®Google Scholar
• Makal GB , Güvençİ. The role of shear wave elastography in differentiating idiopathic granulomatous mastitis from breast cancer. Acad. Radiol.28(3), 339–344 (2021).
   PubMed Web of Science ®Google Scholar
• Ma Y , ZhangS, LiJet al. Comparison of strain and shear-wave ultrasounic elastography in predicting the pathological response to neoadjuvant chemotherapy in breast cancers. Eur. Radiol.27(6), 2282–2291 (2017).
   PubMed Web of Science ®Google Scholar
• Zhao H , HuH, ChenBet al. Overview on the role of E-cadherin in gastric cancer: dysregulation and clinical implications. Front. Mol. Biosci.8, 689139 (2021).
   PubMed Web of Science ®Google Scholar
• Yang J , XiongY, ZhouLet al. Soluble E-cadherin is associated with oxidative stress in patients with chronic HBV infection. J. Med. Virol.92(1), 34–44 (2020).
   PubMed Web of Science ®Google Scholar
• Kawaguchi K , KomodaK, MikawaRet al. Cellular senescence promotes cancer metastasis by enhancing soluble E-cadherin production. iScience24(9), 103022 (2021).
   PubMed Web of Science ®Google Scholar
• Dwedar FI , Shams-EldinRS, NayerMohamed Set al. Potential value of circulatory microRNA10b gene expression and its target E-cadherin as a prognostic and metastatic prediction marker for breast cancer. J. Clin. Lab. Anal.35(8), e23887 (2021).
   PubMed Web of Science ®Google Scholar
• Hofmann G , BalicM, DandachiNet al. The predictive value of serum soluble E-cadherin levels in breast cancer patients undergoing preoperative systemic chemotherapy. Clin. Biochem.46(15), 1585–1589 (2013).
   PubMed Web of Science ®Google Scholar
• Honda Y , YonedaM, ImajoK, NakajimaA. Elastography techniques for the assessment of liver fibrosis in non-alcoholic fatty liver disease. Int. J. Mol. Sci.21(11), 4039 (2020).
   PubMed Web of Science ®Google Scholar
• Hammond ME , HayesDF, DowsettMet al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). Arch. Pathol. Lab. Med.134(7), e48–e72 (2010).
   PubMed Web of Science ®Google Scholar
• Wolff AC , HammondMEH, AllisonKHet al. Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline focused update. J. Clin. Oncol.36(20), 2105–2122 (2018).
   PubMed Web of Science ®Google Scholar
• Taylor-Stokes G , MitraD, WallerJet al. Treatment patterns and clinical outcomes among patients receiving palbociclib in combination with an aromatase inhibitor or fulvestrant for HR+/HER2-negative advanced/metastatic breast cancer in real-world settings in the US: results from the IRIS study. Breast43, 22–27 (2019).
   PubMed Web of Science ®Google Scholar
• Denis M , GregoryA, BayatMet al. Correlating tumor stiffness with immunohistochemical subtypes of breast cancers: prognostic value of comb-push ultrasound shear elastography for differentiating luminal subtypes. PLOS ONE11(10), e0165003 (2016).
   PubMed Web of Science ®Google Scholar
• Bayat M , DenisM, GregoryAet al. Diagnostic features of quantitative comb-push shear elastography for breast lesion differentiation. PLOS ONE12(3), e0172801 (2017).
   PubMed Web of Science ®Google Scholar
• Cosgrove DO , BergWA, DoréCJet al. Shear wave elastography for breast masses is highly reproducible. Eur. Radiol.22(5), 1023–1032 (2012).
   PubMed Web of Science ®Google Scholar
• Mao YJ , LimHJ, NiMet al. Breast tumour classification using ultrasound elastography with machine learning: a systematic scoping review. Cancers (Basel)14(2), 367 (2022).
   PubMed Web of Science ®Google Scholar
• Youk JH , GweonHM. Shear-wave elastography in breast ultrasonography: the state of the art. Ultrasonography36(4), 300–309 (2017).
   PubMed Web of Science ®Google Scholar
• Evans A , ArmstrongS, WhelehanPet al. Can shear-wave elastography predict response to neoadjuvant chemotherapy in women with invasive breast cancer? Br. J. Cancer 109(11), 2798–2802 (2013).
   PubMed Web of Science ®Google Scholar
• Gu J , PolleyEC, TernifiRet al. Individualized-thresholding shear wave elastography combined with clinical factors improves specificity in discriminating breast masses. Breast54, 248–255 (2020).
   PubMed Web of Science ®Google Scholar
• Hao Y , YangW, ZhengWet al. Tumor elastography and its association with cell-free tumor DNA in the plasma of breast tumor patients: a pilot study. Quant. Imaging Med. Surg.11(8), 3518–3534 (2021).
   PubMed Web of Science ®Google Scholar
• Botnariuc I , IlieSM, TrifanescuOGet al. Predictive circulating markers for anthracycline chemotherapy in non-metastatic breast cancer. Acta Endocrinol. (Buchar.)13(2), 209–214 (2017).
   PubMed Web of Science ®Google Scholar
• Ma Y , ZhangS, ZangLet al. Combination of shear wave elastography and Ki-67 index as a novel predictive modality for the pathological response to neoadjuvant chemotherapy in patients with invasive breast cancer. Eur. J. Cancer69, 86–101 (2016).
   PubMed Web of Science ®Google Scholar
• von Minckwitz G , BlohmerJU, CostaSDet al. Response-guided neoadjuvant chemotherapy for breast cancer. J. Clin. Oncol.31(29), 3623–3630 (2013).
   PubMed Web of Science ®Google Scholar
• Pérez-García JM , GebhartG, RuizBorrego Met al. Chemotherapy de-escalation using an 18F–FDG–PET-based pathological response-adapted strategy in patients with HER2-positive early breast cancer (PHERGain): a multicentre, randomised, open-label, non-comparative, phase 2 trial. Lancet Oncol.22(6), 858–871 (2021).
   PubMed Web of Science ®Google Scholar